Matrix Metalloproteinases After Surgery and/or Radiofrequency Ablation in Patients With Liver Metastases From Colorectal Cancer

Study of Diagnostic Tests Studying Kinetic Variation of Serum Matrix Metalloproteases After Surgical Treatment and/or Destruction by Radiofrequency in Patients With Hepatic Metastases From Colorectal Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00899210

Enrollment

Registered

2009-05-12

Start date

2003-09-30

Completion date

Unknown

Last updated

2011-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer, Metastatic Cancer

Keywords

liver metastases, adenocarcinoma of the colon, stage IV colon cancer, adenocarcinoma of the rectum, stage IV rectal cancer, recurrent colon cancer, recurrent rectal cancer

Brief summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research trial is studying matrix metalloproteinases after surgery or radiofrequency ablation in patients with liver metastases from colorectal cancer.

Detailed description

OBJECTIVES: Primary * Describe the kinetics of postoperative changes of serum matrix metalloproteinases (MMP) (MMP-1, MMP-2, MMP-7, MMP-9) and their inhibitors (TIMP) (TIMP-1, TIMP-2) as a function of surgical technique. Secondary * Determine the predictive value of postoperative risk of recurrence. * Correlate the risk of recurrence with surgical technique. * Determine whether elevated serum levels of MMP are a better marker than the carcinoembryonic antigen of hepatic or extrahepatic recurrence. * Determine whether the postoperative serum of HGF/SF is correlated to changes in plasma levels of MMPs. OUTLINE: Blood samples are collected periodically before and after treatment to analyze for metalloproteinases and their inhibitors. After completion of study treatment, patients are followed at day 45 and then every 3 months for 2 years.

Interventions

OTHERlaboratory biomarker analysis

PROCEDUREcryosurgery

PROCEDUREradiofrequency ablation

PROCEDUREtherapeutic conventional surgery

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Meets 1 of the following criteria: * Patients with histologically confirmed adenocarcinoma of the colon or rectum and liver metastases * Must have undergone prior complete resection of the tumor more than 3 months ago * Liver metastases must be resectable or accessible for radiofrequency ablation * Patients undergoing cryosurgery of the digestive tract for a reason other than cancer or infection (control) PATIENT CHARACTERISTICS: * No other neoplastic disease that is measurable or being treated other than colorectal cancer * No heart failure or severe respiratory disease * No uncontrolled infection or other severe disease PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No participation in another study involving new drugs

Design outcomes

Primary

Measure	Time frame
Kinetics of postoperative changes of serum matrix metalloproteinases (MMP) and their inhibitors (TIMP)	—

Secondary

Measure	Time frame
Predictive value of postoperative risk of recurrence	—
Correlation of risk of recurrence with surgical technique	—
Elevated serum levels of MMP vs carcinoembryonic antigen as a marker of hepatic or extrahepatic recurrence	—
Correlation of postoperative serum HGF/SF with plasma levels in MMPs	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026